A detailed history of Merit Financial Group, LLC transactions in Exelixis, Inc. stock. As of the latest transaction made, Merit Financial Group, LLC holds 69,341 shares of EXEL stock, worth $2.68 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares
69,341
Previous 40,760 70.12%
Holding current value
$2.68 Million
Previous $1.8 Million 59.41%
% of portfolio
0.03%
Previous 0.02%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Oct 20, 2025

BUY
$36.22 - $46.25 $1.04 Million - $1.32 Million
28,581 Added 70.12%
69,341 $2.86 Million
Q2 2025

Jul 22, 2025

BUY
$34.13 - $46.26 $249,387 - $338,021
7,307 Added 21.84%
40,760 $1.8 Million
Q1 2025

Apr 09, 2025

BUY
$32.38 - $39.16 $658,123 - $795,926
20,325 Added 154.82%
33,453 $1.24 Million
Q4 2024

Jan 15, 2025

BUY
$25.39 - $36.46 $333,319 - $478,646
13,128 New
13,128 $437,000

Others Institutions Holding EXEL

About EXELIXIS, INC.


  • Ticker EXEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 321,832,000
  • Market Cap $12.4B
  • Description
  • Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...
More about EXEL
Track This Portfolio

Track Merit Financial Group, LLC Portfolio

Follow Merit Financial Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Merit Financial Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Merit Financial Group, LLC with notifications on news.